BCL2 and acute myeloid leukemia: In secondary AML refractory to HMAs, an increase in BCL2 and/or BIM protein detected by immunohistochemistry in myeloblasts in pretreated bone marrow aspirates was strongly associated with venetoclax monotherapy response and overall survival[137].